Sepiapterin Enables Liberalisation of Natural Protein Intake While Improving Metabolic Control in Adolescents with Phenylketonuria
- 1Birmingham Children’s Hospital, Steelhouse Lane, Birmingham B4 6NH, UK
Abstract
Background: Sepiapterin is a synthetic precursor of tetrahydrobiopterin (BH4) that increases intracellular BH4 availability and has demonstrated greater phenylalanine-lowering efficacy than sapropterin. We evaluated its effect on dietary liberalisation and metabolic control in adolescents with phenylketonuria (PKU). Methods: Seven adolescents with PKU (median age of commencing sepiapterin: 13 years, range 12–17 years), including five previously responsive to sapropterin, were studied. Median natural protein intake, protein equivalent from protein substitute, and total protein intake were compared during diet-only treatment, sapropterin treatment (where applicable), and after 12 months of sepiapterin. Blood phenylalanine (Phe) and tyrosine (Tyr) concentrations were assessed over 12 months for each treatment period. Results: Median natural protein intake increased from 6.5 g/day (range 4.5–15) during diet-only treatment (n = 7) to 20 g/day (10–25) with sapropterin (n = 5) and 70 g/day (34–90) after 12 months of sepiapterin (n = 7). This represented a median increase of 218% (70–471%) compared with sapropterin and 600% (200–1900%) compared with diet alone. Median total protein intake on sepiapterin was 90 g/day (70–114), equivalent to 1.4 g/kg/day, and four participants discontinued protein substitute completely. Mean (±SD) blood Phe concentrations were lower with reduced variability on sepiapterin (303 ± 157 µmol/L during diet-only treatment; 321 ± 136 µmol/L with sapropterin; 260 ± 116 µmol/L with sepiapterin), while Tyr concentrations remained stable. The percentage of blood Phe concentrations within target improved with sepiapterin (≤360 µmol/L: 83%, range 77–100) compared with diet alone (68%, range 17–100) and sapropterin (66%, range 40–91). Most participants incorporated high-protein foods into their diets, including meat (7/7), fish (6/7), cheese (6/7), and milk or yoghurt (5/7). Conclusions: Twelve months of sepiapterin enabled marked dietary liberalisation while improving metabolic control in adolescents with PKU. These findings suggest that sepiapterin may substantially reduce treatment burden and represent an important advance in the management of this challenging age group.
Related
- Longitudinal Metabolic Control in Children With Early-Treated Phenylketonuria
- Professionals' perspectives on barriers to improving psychosocial care for adolescents with emotional and behavioural problems - a concept mapping case study.
- Improving reproductive health self-efficacy among female adolescents through audiovisual based education: A pre-experimental study
- The effectiveness of the Youth-Oriented Mental Health Education Program (Y-MIND) school-based psychoeducational program in improving mental health literacy and reducing psychological distress among adolescents in Klaten, Indonesia: A quasi-experimental study
- Developing a systems-based programme theory for reducing night-time interactive electronic device use and improving sleep among adolescents
BibTeX
@article{pinto2026sepiapterin,
title = {{Sepiapterin Enables Liberalisation of Natural Protein Intake While Improving Metabolic Control in Adolescents with Phenylketonuria}},
author = {Alex Pinto and Anne Daly and Suresh Vijay and Sharon Evans and Anita MacDonald},
journal = {Nutrients},
year = {2026},
month = oct,
doi = {10.3390/nu18203376},
url = {https://www.mdpi.com/2072-6643/18/20/3376},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Sepiapterin Enables Liberalisation of Natural Protein Intake While Improving Metabolic Control in Adolescents with Phenylketonuria
AU - Alex Pinto
AU - Anne Daly
AU - Suresh Vijay
AU - Sharon Evans
AU - Anita MacDonald
PY - 2026
DA - 2026/10/15
JO - Nutrients
DO - 10.3390/nu18203376
UR - https://www.mdpi.com/2072-6643/18/20/3376
AB - Background: Sepiapterin is a synthetic precursor of tetrahydrobiopterin (BH4) that increases intracellular BH4 availability and has demonstrated greater phenylalanine-lowering efficacy than sapropterin. We evaluated its effect on dietary liberalisation and metabolic control in adolescents with phenylketonuria (PKU). Methods: Seven adolescents with PKU (median age of commencing sepiapterin: 13 years, range 12–17 years), including five previously responsive to sapropterin, were studied. Median natural protein intake, protein equivalent from protein substitute, and total protein intake were compared during diet-only treatment, sapropterin treatment (where applicable), and after 12 months of sepiapterin. Blood phenylalanine (Phe) and tyrosine (Tyr) concentrations were assessed over 12 months for each treatment period. Results: Median natural protein intake increased from 6.5 g/day (range 4.5–15) during diet-only treatment (n = 7) to 20 g/day (10–25) with sapropterin (n = 5) and 70 g/day (34–90) after 12 months of sepiapterin (n = 7). This represented a median increase of 218% (70–471%) compared with sapropterin and 600% (200–1900%) compared with diet alone. Median total protein intake on sepiapterin was 90 g/day (70–114), equivalent to 1.4 g/kg/day, and four participants discontinued protein substitute completely. Mean (±SD) blood Phe concentrations were lower with reduced variability on sepiapterin (303 ± 157 µmol/L during diet-only treatment; 321 ± 136 µmol/L with sapropterin; 260 ± 116 µmol/L with sepiapterin), while Tyr concentrations remained stable. The percentage of blood Phe concentrations within target improved with sepiapterin (≤360 µmol/L: 83%, range 77–100) compared with diet alone (68%, range 17–100) and sapropterin (66%, range 40–91). Most participants incorporated high-protein foods into their diets, including meat (7/7), fish (6/7), cheese (6/7), and milk or yoghurt (5/7). Conclusions: Twelve months of sepiapterin enabled marked dietary liberalisation while improving metabolic control in adolescents with PKU. These findings suggest that sepiapterin may substantially reduce treatment burden and represent an important advance in the management of this challenging age group.
SN - 2072-6643
ER -